NCT00302471 - MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Prostatic Neoplasms

Interventions

DRUG

Comparator: MK0429

"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."

DRUG

Comparator: MK0429

Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.

DRUG

Comparator: MK0429

Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.

DRUG

Comparator: MK0429

Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY